{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Atlas of MS coming soon!

On Monday 14 August 2006 the results of the MSIF/World Health Organization major survey of the epidemiology of MS and country resources for people with MS in 64 countries worldwide will be made available with the launch of the Atlas of MS website.

read more

French edition of the Principles to Promote the Quality of Life of People with MS is now available to download

MSIF is delighted that the French edition of the Principles to Promote the Quality of Life of People with MS is now available to download from the World of MS website.

read more

Wanted - interview with a young care-giver

Issue 9 of MS in focus, MSIF's bi-annual magazine, will focus on care-givers of people with MS. As part of the magazine, we would like to interview a young care-giver who has experienced a transition or change in their caring situation.

read more

back to top

Profile of the Month : January 2008

Yasmine Rwanyindo

Country: Rwanda
Age: 38
Year of diagnosis: August 2003
Occupation: Administrative and financial manager for a project

English Spanish Italian Russian French German

read more

back to top

Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis.

This study demonstrates that lesional and non-lesional magnetization transfer ratio values (a parameter that estimates the amount of tissue damage occurring in multiple sclerosis) can be significantly less pronounced in benign multiple sclerosis than in a cohort of RR patients at their earliest disease stages, suggesting that brain tissue damage is milder in benign multiple sclerosis than in early RR disease. This can be due to an extraordinary beneficial response to demyelination of benign patients and may represent the evidence that benign multiple sclerosis truly exists and might be differentiated from other forms of this illness.

authors: De Stefano N, Battaglini M, Stromillo ML, Zipoli V, Bartolozzi ML, Guidi L, Siracusa G, Portaccio E, Giorgio A, Sorbi S, Federico A, Amato MP.

source: Brain. 2006 Aug;129(Pt 8):2008-16. Epub 2006 Jun 30.

read more

The value of animal models for drug development in multiple sclerosis.

In this paper the authors suggest some potential explanations based on new thinking about key pathogenic concepts and differences that may limit extrapolation from the rodent model for multiple sclerosis, experimental allergic (autoimmune) encephalomyelitis to multiple sclerosis. To try to circumvent these rodent-human dissimilarities more systematically, they propose that pre-clinical trials should be started in humanized mouse models.

authors: Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L.

source: Brain. 2006 Aug;129(Pt 8):1940-52. Epub 2006 Apr 24.

read more

Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis.

This study demonstrates that two chemokines, MCP-1/CCL2 and IP-10/CXCL10 produced by astrocytes, may activate astrocytes and direct reactive gliosis. Targeting chemokines especially in secondary progressive MS may therefore be a powerful therapeutic approach to inhibit lesional expansion.

authors: Tanuma N, Sakuma H, Sasaki A, Matsumoto Y.

source: Acta Neuropathol (Berl). 2006 Aug;112(2):195-204. Epub 2006 May 30.

read more

Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis.

This study demonstrates that murine ciliary neurotrophic factor inhibits inflammation in the spinal cord, resulting in amelioration of the clinical course of experimental autoimmune encephalomyelitis, an experimental model of MS, during time of treatment.

authors: Kuhlmann T, Remington L, Cognet I, Bourbonniere L, Zehntner S, Guilhot F, Herman A, Guay-Giroux A, Antel JP, Owens T, Gauchat JF.

source: Am J Pathol. 2006 Aug;169(2):584-98.

read more

Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.

This study shows that the clinical improvement of active MS following the treatment with methylprednisolone is associated with the modification of cerebrospinal fluid levels of CCL2 and CXCL10, suggesting that these chemokines may be useful markers of response to treatment and relapses in MS patients.

authors: Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL.

source: Acta Neurol Scand. 2006 Aug;114(2):109-13

read more

back to top

MS professional network conference in Scotland

source: UK MS Society

The MS Society in Scotland are holding this year's professionals' conference on Thursday 14 September at Macdonald Inchyra Grange Hotel, near Falkirk in Scotland.

read more

Latest research news from NZ MS Society

source: NZ MS Society

This time in RoundUp: tetanus shot may curb multiple sclerosis risk, small study combines Novantrone and Copaxone as potential MS treatment, and a possible diagnostic tool for paediatric MS.

read more

New publication on cognitive dysfunction in MS

source: Demos Medical Publishing

Demos has recently published a new title, Multiple Sclerosis: Understanding the Cognitive Challenges, by Nicholas LaRocca, PhD, and Rosalind Kalb, PhD.

read more

Study suggests tetanus vaccination associated with lower risk of developing MS

source: US National MS Society

A recently published study by Harvard researchers reported that people who had received tetanus vaccine were one-third less likely to develop multiple sclerosis than those who had not been vaccinated.

read more

US National MS Society offers new funding in healthcare delivery research

source: US National MS Society

The US National Multiple Sclerosis Society has released its annual Request for Proposals inviting applications from qualified investigators for studies in health care delivery and policy research.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.